Randomized Phase II Trial of Inhaled Budesonide versus Placebo in High-Risk Individuals with CT Screen–Detected Lung Nodules
Authors:
- Giulia VeronesiGVGiulia Veronesi
- Eva SzaboESEva Szabo
- Andrea DeCensiADAndrea DeCensi
- Aliana Guerrieri-GonzagaAGAliana Guerrieri-Gonzaga
- Massimo BellomiMBMassimo Bellomi
- Davide RadiceDRDavide Radice
- Stefania FerrettiSFStefania Ferretti
- Giuseppe PelosiGPGiuseppe Pelosi
- Matteo LazzeroniMatteo Lazzeroni
- Davide SerranoDSDavide Serrano
- Scott M. LippmanSLScott M. Lippman
- Lorenzo SpaggiariLSLorenzo Spaggiari
- 1 January 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 4 (1) , 34-42
Abstract
Screening CT identifies small peripheral lung nodules, some of which may be pre- or early invasive neoplasia. Secondary end point analysis of a previous chemoprevention trial in individuals with bronchial dysplasia showed reduction in size of peripheral nodules by inhaled budesonide. We performed a randomized, double-blind, placebo-controlled phase IIb trial of inhaled budesonide in current and former smokers with CT-detected lung nodules that were persistent for at least 1 year. A total of 202 individuals received inhaled budesonide, 800 μg twice daily or placebo for 1 year. The primary endpoint was the effect of treatment on target nodule size in a per person analysis after 1 year. The per person analysis showed no significant difference between the budesonide and placebo arms (response rate 2% and 1%, respectively). Although the per lesion analysis revealed a significant effect of budesonide on regression of existing target nodules (P = 0.02), the appearance of new lesions was similar in both groups and thus the significance was lost in the analysis of all lesions. The evaluation by nodule type revealed a nonsignificant trend toward regression of nonsolid and partially solid lesions after budesonide treatment. Budesonide was well tolerated, with no unexpected side effects identified. Treatment with inhaled budesonide for 1 year did not significantly affect peripheral lung nodule size. There was a trend toward regression of nonsolid and partially solid nodules after budesonide treatment. Because a subset of these nodules is more likely to represent precursors of adenocarcinoma, additional follow-up is needed. Cancer Prev Res; 4(1); 34–42. ©2010 AACR.Keywords
This publication has 38 references indexed in Scilit:
- Budesonide versus placebo in high-risk population with screen-detected lung nodules: Rationale, design and methodologyContemporary Clinical Trials, 2010
- Chemoprevention of Lung CancerProceedings of the American Thoracic Society, 2009
- Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodulesLung Cancer, 2008
- Ground-Glass Opacities on Thin-Section Helical CT: Differentiation Between Bronchioloalveolar Carcinoma and Atypical Adenomatous HyperplasiaAmerican Journal of Roentgenology, 2008
- Persistent Pulmonary Nodular Ground-Glass Opacity at Thin-Section CT: Histopathologic ComparisonsRadiology, 2007
- Inhaled Corticosteroids and Risk of Lung Cancer among Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Survival of Patients with Stage I Lung Cancer Detected on CT ScreeningNew England Journal of Medicine, 2006
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Early Lung Cancer Action Project: overall design and findings from baseline screeningThe Lancet, 1999